High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
8 Analyst Rating
Wall Street analysts forecast ABVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABVX is 129.25 USD with a low forecast of 101.00 USD and a high forecast of 176.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 110.640
Low
101.00
Averages
129.25
High
176.00
Current: 110.640
Low
101.00
Averages
129.25
High
176.00
Truist
Gregory Renza
Buy
initiated
$140
2025-11-24
Reason
Truist
Gregory Renza
Price Target
$140
2025-11-24
initiated
Buy
Reason
Truist analyst Gregory Renza initiated coverage of Abivax with a Buy rating and $140 price target. Following a second-half re-rate from phase 3 induction data in ulcerative colitis, investors are focused on obefazimod's increasing value proposition and set-up for key phase 3 UC maintenance data in Q2 of 2026 and phase 2b induction topline in Crohn's disease coming the second half of 2026, the analyst tells investors in a research note. Obefazimod represents an unusual mechanism of action, which the firm views as being backed by preclinical and clinical evidence indicating broad immunological effects, Truist added.
Wolfe Research
Outperform
initiated
$176
2025-11-05
Reason
Wolfe Research
Price Target
$176
2025-11-05
initiated
Outperform
Reason
Wolfe Research initiated coverage of Abivax with an Outperform rating and $176 price target. The company's odds of success in Crohn's disease may be higher than that of ulcerative colitis, the analyst tells investors in a research note. The firm says that with ulcerative colitis already succeeding, and with obefazimod having a better mechanism for Crohn's disease, the Crohn's readout is a better catalyst in 2026.
Citizens JMP
Outperform
maintain
$95 -> $114
2025-09-25
Reason
Citizens JMP
Price Target
$95 -> $114
2025-09-25
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Abivax to $114 from $95 and keeps an Outperform rating on the shares after the company announced that results from the obefazimod Phase 3 induction trials will be presented next month. The firm believes the Phase 3 results can reinforce the strength of obefazimod's efficacy, and increase conviction in its multi-billion dollar sales potential. In anticipation, Citizens increased the drug's peak sales estimates.
Morgan Stanley
NULL -> Overweight
upgrade
$71 -> $101
2025-09-12
Reason
Morgan Stanley
Price Target
$71 -> $101
2025-09-12
upgrade
NULL -> Overweight
Reason
Morgan Stanley raised the firm's price target on Abivax to $101 from $71 and keeps an Overweight rating on the shares. After the company reported first half results and attended the firm's Global Healthcare Conference, the analyst sees higher odds of success for the Crohn's indication for obefazimod following discussions with management.
Piper Sandler
NULL
to
Overweight
upgrade
$70 -> $112
2025-07-29
Reason
Piper Sandler
Price Target
$70 -> $112
2025-07-29
upgrade
NULL
to
Overweight
Reason
Piper Sandler raised the firm's price target on Abivax to $112 from $70 and keeps an Overweight rating on the shares. After fully digesting obefazimod Phase 3 induction data in ulcerative colitis, the firm thinks it's appropriate to layer in revenue in early-line UC, and doing so essentially doubles its U.S. UC revenue estimate to EUR 2,656M in 2035. Thus, Piper still believes there's significant upside that can make its way into the stock heading into key data events.
Citizens JMP
Jason Butler
Outperform
upgrade
$33 -> $95
2025-07-23
Reason
Citizens JMP
Jason Butler
Price Target
$33 -> $95
2025-07-23
upgrade
Outperform
Reason
Citizens JMP analyst Jason Butler raised the firm's price target on Abivax to $95 from $33 and keeps an Outperform rating on the shares. "Stellar" Phase 3 results for obefazimod in ulcerative colitis support the potential for broad and early use in clinical practice, the analyst tells investors in a research note. The positive results from the two Phase 3 induction trials are highly compelling, with a pooled, placebo-adjusted clinical remission rate of 16.4% and a clean safety and tolerability profile, the firm says.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Abivax SA (ABVX.O) is -33.77, compared to its 5-year average forward P/E of -8.00. For a more detailed relative valuation and DCF analysis to assess Abivax SA 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-8.00
Current PE
-33.77
Overvalued PE
4.06
Undervalued PE
-20.05
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-13.31
Current EV/EBITDA
-37.39
Overvalued EV/EBITDA
14.39
Undervalued EV/EBITDA
-41.01
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
270.37
Current PS
336.55
Overvalued PS
957.06
Undervalued PS
-416.31
Financials
Annual
Quarterly
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
ABVX News & Events
Events Timeline
(ET)
2025-11-03
17:11:18
Abivax Reveals Patient-Reported Results from ABTECT Study
2025-07-24 (ET)
2025-07-24
08:47:36
Abivax 10.16M ADS offering priced at $64.00
2025-07-24
08:45:40
Abivax prices 10.2M ADSs at $64.00 in underwritten public offering
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/fc5119f47a6cf740ad7cc03c4d70ba9fd520f1d16e0d08bea13c1816ce99083f.jpg)
Preview
4.0
11-26NASDAQ.COMABVX Surpasses Average Analyst Price Target
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/benzinga.png)
Preview
6.0
11-25BenzingaTruist Securities Begins Coverage of Abivax with a Buy Rating and Sets Price Target at $140
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/seekingalpha.png)
Preview
8.5
11-20SeekingAlphaAbivax Rises on Acquisition Rumors
Sign Up For More News
People Also Watch
FAQ
What is Abivax SA (ABVX) stock price today?
What is Abivax SA (ABVX)'s business?
What is the price predicton of ABVX Stock?
What is Abivax SA (ABVX)'s revenue for the last quarter?
What is Abivax SA (ABVX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Abivax SA (ABVX)'s fundamentals?
How many employees does Abivax SA (ABVX). have?